Erdheim-Chester disease is a rare, non-Langerhans cell histiocytosis histologically characterized by multisystemic proliferation of mature histiocytes in a background of inflammatory stroma. The disease can involve virtually any organ system; most commonly the bones, skin, retroperitoneum, heart, orbit, lung, and brain are affected. Although a histiocytic proliferation is the histological hallmark of the disease, a wide range of morphological appearances have been described as part of case studies or small series. A comprehensive review of histopathological features in clinically and molecularly defined Erdheim-Chester disease has yet to be characterized. To address this issue and help guide clinical practice, we comprehensively analyzed the pathological spectrum of Erdheim-Chester disease in a clinically and molecularly defined cohort. We reviewed 73 biopsies from 42 patients showing involvement by histiocytosis from a variety of organ systems, including bone (16), retroperitoneum (11), skin (19), orbit (6), brain (5), lung (6), cardiac structures (2), epidural soft tissue (3), oral cavity (2), subcutaneous soft tissue (2), and testis (2). In eight patients, one or more bone marrow biopsies were performed due to clinical indication and an accompanying myeloid neoplasm was detected in six of them. Thirty-eight cases were investigated for genetic abnormalities. Somatic mutations involving BRAF (25/38), MAP2K1 (6/38), ARAF (2/38), MAP2K2 (1/38), KRAS (1/38), and NRAS (1/38) genes were detected. One of the cases with a MAP2K1 mutation also harbored a PIK3CA mutation. We have observed marked heterogeneity in histology and immunophenotype, identified site-specific features, overlap with other histiocytic and myeloid disorders and potential diagnostic pitfalls. We hope that broadening the spectrum of recognized pathologic manifestations of Erdheim-Chester disease will help practicing clinicians and pathologists to diagnose Erdheim-Chester disease early in the disease course and manage these patients effectively.
Erdheim-Chester disease is a rare, non-Langerhans cell histiocytosis histologically characterized by multi-systemic proliferation of mature histiocytes in a background of inflammatory stroma. The infiltrate can occur in virtually any organ system although most commonly involves the bones, skin, retroperitoneum, heart, orbits, lung, and brain. [1] [2] [3] Clinical manifestations in Erdheim-Chester disease is mediated by local effects of the histiocytic infiltrate, as well as by chronic systemic inflammation and cytokine perturbations. 4 The etiology and pathogenesis of Erdheim-Chester disease were largely unclear until recently; however, the discovery of (1) recurrent BRAF V600E mutations in lesional tissue, 5 and then (2) an array of other activating mitogen-activated protein kinase (MAPK) pathway mutations 6 have established the neoplastic nature of the disease and led to designation of ErdheimChester disease as a histiocytic neoplasm. Altogether, Erdheim-Chester disease is now considered a clonal hematopoietic disorder marked by recurrent MAPK pathway genetic alterations, with clinical manifestations caused by neoplastic histiocytic infiltrates and uncontrolled inflammation.
Consensus diagnostic criteria for Erdheim-Chester disease require (1) xanthogranulomatous lesions characterized by foamy CD68(+)/CD1a(− ) histiocytes, often with admixed inflammation and fibrosis, and (2) skeletal findings of bilateral and symmetric abnormalities in the diaphyseal and metaphyseal regions of the long bones of the legs. 7 All patients were evaluated at least once in consultation at our center. The bone involvement may appear as osteosclerotic lesions by plain film or computed tomography (CT), or it can be visualized by 99 Technetium bone scan. Owing to the frequent absence of bone pain, the wide anatomic distribution of ErdheimChester disease lesions, and the protean clinical manifestations of disease, extraosseous lesions are frequently those identified and sampled initially. Furthermore, it has been observed in recent studies that Erdheim-Chester disease lesions can be heterogeneous in their cellular composition and do not invariably demonstrate xanthomatous histiocytes. 7 In fact, some lesions in well-established ErdheimChester disease may have a scant presence of lesional histiocytes and variable stromal components of acute and chronic inflammation. For this reason, establishing or more importantly suspecting a diagnosis of Erdheim-Chester disease can be hindered by reliance upon iconic or 'classic' morphology in biopsy material.
To our knowledge, a comprehensive and systematic description of histopathological features of Erdheim-Chester disease lesions beyond the classic xanthomatous infiltrate has not been performed. In this report, we present the wide spectrum of histopathologic and immunohistochemical phenotypes in a well-characterized, molecularly defined cohort of Erdheim-Chester disease patients from a single institution. Histopathologic features of lesions from bone, brain, retroperitoneum, skin, orbit, lung, subcutaneous and epidural soft tissues, heart, oral cavity, and testis are demonstrated. When available, the genomic alterations present in lesional tissue are presented. We hope and anticipate that broadening the spectrum of recognized pathologic manifestations of Erdheim-Chester disease will aid in its diagnosis for practicing clinicians and pathologists.
Materials and methods

Patient Selection and Histopathologic Evaluation
This study was conducted according to the Declaration of Helsinki, and human tissues were obtained and analyzed with procedures approved by the Institutional Review Board of Memorial Sloan Kettering Cancer Center. For all patients, ErdheimChester disease was diagnosed in light of published guidelines for the diagnosis and clinical management of Erdheim-Chester disease and in light of institutional experience with this disease. 7 In our cohort, all patients but one had radiologic abnormalities in the femora or tibia demonstrable by one or more of the following: CT, MRI, 99 Tc nucleotide bone scan, or ( 18 F)-Fluorodeoxyglucose (FDG) PET scan. Biopsy material was retrieved from the pathology archives, or from the evaluation of active clinical cases, at Memorial Sloan Kettering Cancer Center. Available hematoxylin-eosin slides and immunohistochemical slides were examined, and additional immunohistochemical studies were performed, if unstained material was available. Immunohistochemical analysis was performed on paraffin sections for CD163 (Ventana, cat no: #760.4437, clone MRQ-26), CD68 (Ventana, cat no: #790-2931, clone KP1), BRAF V600E (cat no: Spring, #E19294, clone VE1), S100 (DAKO, cat no: #Z0311, rabbit polyclonal), CD1a (Cell Marque, cat no: #760-4525, clone EP3622), Factor XIIIa (Cell Marque, cat no: #760-4384, clone AC-1A1), and Langerin (Leica, cat no: #NCL-L-Langerin, clone 2D6). Immunohistochemical staining was performed with BondIII (Leica-Microsystems, Buffalo Groove, IL).
Molecular Analysis of Erdheim-Chester Disease Patient Tissue Samples
Genomic DNA was extracted from formalin-fixed, paraffin-embedded samples after histologic review and enrichment by macrodissection to ≥10% histiocytes, and all materials were from pre-treatment samples. Detection of the BRAF V600E mutation was performed by pyro-sequencing. 8 Screening for mutations in other genes was performed with sequenom mass spectrometric-based genotyping assays as previously described (NRAS, KRAS, PIK3CA, and AKT1 hotspot mutations), and whole-exome sequencing analysis. 9 For patients undergoing whole-exome sequencing, disease DNA was extracted from frozen biopsies while paired germline DNA was extracted from peripheral blood mononuclear cells.
Urine cfDNA was isolated as previously described. 10 Urine cfDNA was quantified by a droplet-digital polymerase chain reaction (ddPCR; QX-100, BioRad) assay to a 44-bp amplicon of RNase P, a single-copy gene, as previously described. 10 Quantified DNA up to 60 ng was used for mutation detection of BRAF V600E by ddPCR.
Two of our patients have been previously described in the form of individual case reports, 11, 12 and 11 patients were also studied by whole-exome sequencing or targeted sequencing previously. 9, 13 
Results
The study population (Table 1) consisted of 42 patients with a total of 73 available biopsy specimens involved by histiocytosis. Sixteen patients had more than one biopsy site. Initial and subsequent therapy is known for 40 patients, and 2 were evaluated in consultation and then lost to follow-up. Initial therapy was interferonalpha for eight patients; this was the only treatment for two patients. The other six were transitioned to anakinra and/or targeted therapy. Anakinra was initial treatment for six patients and has been maintained in two patients while changed to methotrexate, interferon, or targeted therapy for the others. Targeted therapy (BRAF or MEK inhibition) was initial treatment for 14 patients. The remaining patients' initial treatments were methotrexate, cytarabine, imatinib, 6-mercaptopurine, mycophenolate, clofarabine, vinblastine/prednisone, and cladribine. From the time of consultation at our center, the longest period of follow-up is 48 months. Of the 40 patients followed, 4 (10%) have died and the remainder are alive in active follow-up.
Pathological Observations
Morphologic, immunophenotypic and genetic findings are summarized in Table 1 and Supplementary  Table S1 . Given that there were organ site-specific morphological features, these are discussed separately below and also in Table 2 . The bone marrow findings, immunophenotypic, and molecular results are summarized separately at the end of the results section but also referred to in site-specific description where required.
Bone. Fifteen bone biopsies were performed on 14 patients. The lesions were predominantly sampled from the tibia and femur, but one patient had a sacral lesion, one had a scapular lesion and another had a calvarial lesion. Histologically, all lesions involved Modern Pathology (2018) 31, 581-597
Histopathology of Erdheim-Chester disease the medullary cavities of the affected bones with marrow replacement. All lesions had various degrees of histiocytic content; however, classical foamy histiocytes were not necessarily seen in all cases. Cases with mild fibrotic background, loose clusters of classical foamy or granular histiocytes with welldefined cell borders were present ( Figure 1a ). In some cases, however, prominent fibrotic background obscured the morphology, and scant infiltrates comprised of amorphous lipid-laden or granular histiocytes were seen instead of classical morphology ( Figure 1b ). In addition, the calvarial lesion (showed moderate S100 expression) had focally dense aggregates of lymphocytes and plasma cells, mimicking Rosai-Dorfman disease ( Figure 1c) . A certain degree of fibrosis was seen more extensively in all bone biopsies when compared to other tissue sites. Some cases had prominent fibrosis and osteosclerosis ( Figure 1d ). Touton-type giant cells were seen in one case, and reactive bone formation was common. No emperipolesis or necrobiosis was seen and eosinophils were rare. Retroperitoneum. Eleven retroperitoneum biopsies were performed on 11 patients. Microscopically, the typical xanthomatous quality of the Erdheim-Chester disease infiltrate was present in all the retroperitoneal biopsies examined (Figure 2a ), although the variability in lesional composition and microscopic appearance sometimes made the interpretation difficult. In this region, the disease was occasionally accompanied by numerous plasma cells (Figure 2b ). Other inflammatory cells included small lymphocytes, and in rare cases, very few eosinophils. In five cases, immunohistochemical staining for IgG4 was performed due to the presence of a prominent lymphoplasmacytic infiltrate and was either completely negative or highlighted only rare plasma cells. The plasma cells were often located around small vessels. Modern Pathology (2018) 31, 581-597
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IgG4 immunohistochemistry was performed due to the presence of prominent lymphoplasmacytic infiltrates, and were negative.
Central nervous system. We had five patients with biopsy-proven brain involvement. Histologically, brain lesions were less characteristic in their histology compared to Erdheim-Chester disease lesions of other localizations from the same patients. Four cases showed mild to florid cellular infiltrates composed of mononuclear cells arranged in loosely aggregated, formless clusters or present as single cells without associated fibroplasia. The infiltrates were denser in the perivascular areas and consisted of an intermixture of small lymphocytes (mostly T-cells by immunohistochemistry) and histiocytes.
Other types of inflammatory cells, notably eosinophils, were found rarely as isolated cells. The typical histiocyte in these lesions had indistinct cellular margins and non-lipidized cytoplasm, which was mostly pale or more densely eosinophilic (Figure 3a ). CD68 and/or CD163 outlined the histiocytic infiltrate ( Figure 3b ) without expression of CD1a and Langerin. Apart from perivascular localization, the distribution of histiocytes within the background of mononuclear cells was generally haphazard as individual cells or small foci. Many nuclei were round or oval. Grooved or lobulated nuclei were not prominent. Reactive astrocytic proliferation was a constant feature and sometimes was prominent. In the biopsy from two patients, astrogliosis with focally prominent Rosenthal fiber formation was evident and one of them was initially thought to possibly represent Alexander's disease (Figure 3c ). In another patient, areas of myelin deficits with relative preservation of axons were seen (Figures 3e  and f) . This finding in the context of perivascular chronic inflammation with surrounding histiocytic infiltrate and gliosis raised question of multiple sclerosis, though the total and sharply circumscribed type of myelin loss that characterizes classic demyelinating disease was not apparent. The classical foamy and xanthomatous appearance and Toutontype giant cells were seen in only one patient (Figure 3e ). Of note, expression of S100 could not be judged clearly, Lung. Biopsy-proven lung involvement was found in six patients. Five of these patients were neversmokers, whereas 1 patient reported to smoke 1 pack per day for 20 years and had quit 9 years before the Erdheim-Chester disease diagnosis.
The morphologic appearances in all six patients were similar to one another and showed marked thickening of the pleura, interlobular septa, and perivascular interstitium with lesser involvement of the peribronchiolar areas (Figures 4a and b) . The infiltrates were characterized by varying amounts of histiocytic infiltrates and fibrosis (Figure 4c ). The most distinctive feature was an infiltrate of mononuclear histiocytic cells with associated fibrosis in an exquisitely lymphangitic distribution. Wellformed granulomas were not seen. However, in the biopsy from one patient, a loose granuloma-like structure with multinucleated giant cells as well as accompanying intense plasma cell infiltration raised the differential diagnosis with sarcoidosis. But subtle interstitial foamy histiocytic infiltration in adjacent parenchyma was present. The histiocytic cells constantly lacked nuclear grooves typical of Langerhans' cells. No emperipolesis or necrobiosis was seen and eosinophils were rare.
Skin. All of the patients in this group had multiple skin lesions, manifesting as papules or papulonodular lesions. No lesion was ulcerated and no large nodular masses were seen. The anatomic distribution varied, but the face (peri-orbital region) was most commonly affected, followed by the lower extremity. In the absence of therapy, no lesion resolved spontaneously. All but one patient had at least one extracutaneous biopsy documenting Erdheim-Chester disease involvement. This patient had long standing skin lesions in both lower extremities and was diagnosed as multicentric reticulohistiocytosis. Although her clinical status was initially stable, after 10 years, the patient developed dysarthria, ataxia, and bone pain. Previous skin biopsies, systemic clinical findings, and imaging studies were suspicious for Erdheim-Chester disease. Mutation analysis of a skin lesion confirmed the presence of BRAF V600E .
The microscopic findings of 19 biopsies from 7 patients were reviewed. Ten lesions showed classical features of Erdheim-Chester disease characterized by small aggregates of histiocytes in the dermis with xanthomatous features and Touton-type giant cells (Figures 5a and b) . Two lesions contained a neutrophilic infiltrate with microabscesses ( Figure 5c ). In four lesions the histiocytes were displayed in an interstitial/perivascular pattern (Figure 5d ). Five lesions from two patients displayed unusual features, including dermatofibroma-like morphology (Figure 5e ). In some lesions, dense perivascular lymphoid aggregates were seen (Figure 5f ). None of the dermal infiltrates was associated with epidermal changes. The extent of stromal fibrosis was variable. None of the lesions showed emperipolesis or necrobiosis.
Cardiac structures. Biopsies of one atrial mass and one cardiac valve (pulmonary) were performed in two patients. Both of the lesions showed exuberant histiocytic and chronic fibro-inflammatory exudation, which was composed of numerous histiocytes with large vesicular nuclei and moderate amounts of lightly eosinophilic cytoplasm, all with areas of fibrosis seen. Typical foamy histiocytes were seen only in the cardiac valve biopsy (Figure 6a ). In the atrial mass lesion, there was diffuse myocardial involvement, with extension to the depth of the myocardium (Figure 6b ). The reactive lymphoid infiltrate was seen but not prominent. Other types of inflammatory cells were not seen. The extent of stromal fibrosis was variable.
Exceptional Sites of Involvement
Epidural soft tissues. Three biopsies were performed on three patients. Microscopically, the lesions had illdefined margins and revealed a fibrous tumor with rarefied sheets of intermediate-sized, eosinophilic and amorphous histiocytes (Figure 6c ). Interspersed lymphocytes and plasma cells without any aggregate or germinal center formation are seen. In focal areas, foamy histiocytes were present in all three cases. No giant cells, emperipolesis, or necrobiosis were seen; and eosinophils were rare. One of the patients also had multifocal dense deposits of Langerhans cells with indented nuclei and eosinophilic cytoplasm in the same biopsy (Figure 6d ). Immunohistochemical studies proved the co-existence of Langerhans cell histiocytosis aggregates with CD68+/S100+/CD1a+ expression within the Erdheim-Chester disease lesion.
Oral cavity. One tongue biopsy and one tooth extraction were performed on two patients who developed symptomatic lesions. The intraoral lesions were observed after the pathologic diagnosis from omental lesion and chest wall mass, respectively. The first patient presented with a nodule on the anterior ventral tip of the tongue. Excisional biopsy showed a benign squamous mucosa and underlying diffuse infiltration of atypical histiocytes intermixed with moderate amounts of neutrophils resembling granulation tissue (Figure 6e ). Histiocytes were medium to large sized with abundant eosinophilic cytoplasm, round to oval nuclei, and prominent nucleoli. Typical foamy histiocytes were not seen. In the second patient, upon teeth extraction, a round soft tissue lesion with a cystic lumen was noted attached to the mesial wall of the extraction site. Biopsy showed a dispersed histiocytic infiltrate with xanthomatous features among hyalinized stroma, extracellular basophilic matrix, and accompanying giant cells (Figure 6f ).
Subcutaneous soft tissues.
One patient initially presented with a chest wall mass, and another patient developed a soft tissue mass on the upper back during the course of the disease. Following core biopsy, both of the lesions were composed of solid sheets of histiocytic cells with no discernible architecture. All showed similar cytomorphology and classical appearance, being composed of medium-sized, foamy histiocytes with well-defined cell borders in the background of fibrosis. The soft tissue mass from the back was also infiltrated by numerous plasma cells. IgG4 staining was positive in o 40% of the IgG-positive infiltrating plasma cells. The plasmacytic infiltrate was diffuse throughout the biopsy specimen.
Testis. Orchiectomy was performed on two patients who developed testicular lesions seen on PET/CT during the course of disease. Both of the patients had at least one extra-testicular biopsy revealing Erdheim-Chester disease involvement. Both of the testicular biopsies showed lesions with histological features indistinguishable from those of classical Rosai-Dorfman disease (Figures 7a and b) . These include a mixed lympho-plasmacytic infiltrate with interspersed histiocytes with voluminous cytoplasm, emperipolesis, and extensive S100 expression (Figure 7c ). The infiltrates were interstitial and well circumscribed. The surrounding testicular parenchyma was largely unremarkable. One biopsy (Table 1 ; Patient 1) was analyzed for genetic mutations by whole-exome sequencing and showed the same MAP2K1mutation, which was found in the Erdheim-Chester disease lesion in the tongue biopsy.
Bone Marrow Findings
Bone marrow biopsy was concurrently or subsequently performed on eight Erdheim-Chester disease patients. Four patients had chronic myelomonocytic biopsy from a patient with BRAFV600E mutant mixed histiocytosis (Erdheim-Chester disease/Langerhans cell histiocytosis) showed myelodysplastic syndrome. Immunohistochemical studies showed increased CD34-positive blasts (e). Aberrant CD34 expression was also noted in dysplastic megakaryocytes (e, arrows). BM aspirate smear of the same patient demonstrated dysplastic megakaryocytes with widely separated nuclei (f) and nuclear abnormalities in erythroid precursors (binucleation, nuclear budding) (arrow) (g). leukemia-1 (Figure 7d) , one patient had JAK2+ unclassified myeloproliferative neoplasm, one patient had myelodysplastic syndrome with excess blasts-1 (Figures 7e-g ), and two of them had only some reactive changes. Two of the patients who were diagnosed as chronic myelomonocytic leukemia-1 had asymptomatic monocytosis before they were diagnosed as Erdheim-Chester disease. In the follow-up bone marrow biopsy, the patient diagnosed with myelodysplastic syndrome progressed to acute myeloid leukemia with myelodysplasia-related changes within 6 months. Clinical and molecular features of these cases have been reported. 13 
Summary of Immunohistochemical Features
All specimens were positive for one or more of the histiocytic markers including CD68, CD163, or FXIIIa, while all of the specimens were completely negative for CD1a (except the case with concomitant Langerhans cell histiocytosis infiltration). S100 was positive in 12/40 (30%) cases of Erdheim-Chester disease samples (brain and testis biopsies were excluded). IgG4 immunostaining was performed in 10 cases, and none of them reached the 40% cutoff value often required for the diagnosis IgG4-related disease. BRAF V600E immunostaining was performed in 28 samples of 23 patients, 16 with BRAFV600E mutation detected by molecular studies. BRAF V600E immunostain was positive in 14 samples; all BRAFV600E-mutated cases. BRAF V600E immunostain was negative in 14 samples including 2 samples from two different BRAFV600E-mutated cases (one was detected from the lesional tissue, while the other one was detected from the urinary cell-free DNA but not on the lesional tissue by PCR) (Supplementary Table S1 ).
Two cases exhibited features of Erdheim-Chester disease and Langerhans cell histiocytosis. In the first case, the morphologic appearance and immunophenotypic findings were typical for Erdheim-Chester disease in lung and bone and for Langerhans cell histiocytosis in the oropharynx. A second case had aggregates of Langerhans cell histiocytosis in a background of Erdheim-Chester disease infiltration in the same epidural mass lesion.
Summary of Molecular Features
Mutational analysis was performed in 38 cases. Somatic mutations involving BRAF (25/38), MAP2K1 (6/38), ARAF (2/38), MAP2K2 (1/38), KRAS (1/38), and NRAS (1/38) genes were detected (Figure 8) . One of the cases with MAP2K1 mutation also harbored a concurrent PIK3CA mutation. In two cases, no mutation was identified. Molecular analysis detected the same MAP2K1 mutation in the tongue and testis of a patient (Table 1 ; Patient 1) who has an ErdheimChester disease-like appearance in the omental and tongue lesions and Rosai-Dorfman disease-like features in the testis biopsy.
Discussion
In this study, we provide a detailed description of the histopathology of Erdheim-Chester disease in clinical biopsy specimens to help establish pathological diagnosis of Erdheim-Chester disease early in the disease course. Our study shows variability of histopathology from patient to patient but also establishes site-specific patterns, and we also identify important pitfalls in the evaluation of potential Erdheim-Chester disease specimens.
We describe the morphological, immunohistochemical, and molecular spectrum of 42 ErdheimChester disease patients. On the basis of our series, similar with previous reports, Erdheim-Chester disease is predominantly a disease of adulthood, with an age range of 15-75 years (mean 58) with male predominance. In our cohort, two patients had a childhood history of Langerhans cell histiocytosis and developed Erdheim-Chester disease at relatively early ages (28 and 43) ( Table 1 ; Patients 6 and 41). This observation suggests that the Erdheim-Chester disease may possibly represent an end point for some of the Langerhans cell histiocytosis patients.
We also show that myeloid neoplasms can be seen in the course of Erdheim-Chester disease in approximately 15% (6/42) of our case cohort, consistent BRAF V600E 65%
MAP2K1 16%
ARAF 5%
MAP2K2 3%
KRAS 3%
NRAS
3%
Wild Type 5% N = 38 Figure 8 Graphical summary of diverse kinase alterations in the Erdheim-Chester disease study cohort. Pie chart illustrating the activating kinase alterations uncovered in the Erdheim-Chester disease study cases by whole exome sequencing and targeted mutational profiling.
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with what has been recently demonstrated in a multi-center series. 13 Since bone marrow biopsies are not a routine procedure in the work up of Erdheim-Chester disease patients, the exact ratio of accompanying myeloid neoplasms is not known. The presence of concomitant myeloid neoplasms can cause discordant and adverse responses to targeted therapies and also can be associated with a worse prognosis in Erdheim-Chester disease. 13 Therefore, we recommend that a bone marrow biopsy should be routinely performed for the work up of these patients. The pathogenesis of myeloid neoplasms in Erdheim-Chester disease remains unclear but it is likely that at least a subset of the cases may share a common clonal precursor. 13 The results of our study establish a broad range of morphology and clinical behavior in ErdheimChester disease harboring activating mutations of the MAPK pathway. While confirming the wellknown features of this disease, this article documents presentation of Erdheim-Chester disease in previously unreported or unusual sites and unusual infiltration patterns which creates challenges for early and accurate diagnosis.
The histological appearances of Erdheim-Chester disease considerably vary depending on anatomical location of lesions, even in the same patient. If there are any suspicions of a possible Erdheim-Chester disease diagnosis in a particular lesion, the pathologist should request an additional biopsy on another lesion in order to confirm the diagnosis. Brain and skin lesions are especially problematic for an initial Erdheim-Chester disease diagnosis without a corroborating genomic finding.
Since the most common clinical presentation of Erdheim-Chester disease is bone pain and radiographic findings of bone lesions are pathognomonic, bone biopsies are most commonly encountered in clinical practice. Typically, marrow spaces were infiltrated by a cellular population of histiocytic cells showing xanthomatous features in the background of prominent fibrosis, which mostly lacked inflammatory cells. In some lesions, however, mixed inflammatory cells including lymphocytes and plasma cells were focally present, which caused diagnostic challenges in differentiation from RosaiDorfman disease and osteomyelitis. Histologically, the bone lesions must be distinguished from benign fibrous histiocytoma of bone (fibrous xanthoma or xanthofibroma, nonossifying fibroma), Langerhans cell histiocytosis, Rosai-Dorfman disease, xanthogranulomatous inflammation, and fibrous dysplasia with xanthomatous reaction secondary to hemorrhage.
Cutaneous involvement occurs in approximately 20% of cases. Skin lesions are neither characteristic nor specific. Most of the cases show a nodulardiffuse infiltration with foamy histiocytes andmore commonly than other locations-with accompanying Touton-type giant cells. We also noticed that some cases show subtle interstitial-perivascular histiocytic infiltration with variable cytologic features. In one case (Table 1 ; Patient 24) we initially considered an incidental dermatofibroma, since foamy histiocytes and Touton-type giant cells were absent. However, the molecular analysis identified the same MAP2K1 mutation in the dermatofibromalike skin lesion as previously detected in a cardiac valve biopsy with classical morphology, thereby revealing it as an Erdheim-Chester disease lesion. In skin biopsies most important differential diagnoses include other histiocytic disorders and lymphomas. For patients who already have an ErdheimChester disease diagnosis, biopsy of skin lesions, even if not classic, may be a minimally invasive means to establish the mutational status of the patient for targeted therapies.
In contrast to Erdheim-Chester disease involvement in other tissue sites, the histology of lung involvement by Erdheim-Chester disease is distinct. The low-power appearance of Erdheim-Chester disease in pulmonary wedge biopsy specimens is characterized by a strikingly lymphangitic distribution. The infiltrate is detected in the visceral pleura, in the interlobular septa, and around the bronchovascular bundles. Owing to this lymphangitic pattern, the transbronchial biopsy may not be diagnostic and also not appropriate for molecular testing due to lack of lesional histiocytes. Fibrosis typically involves the pleura and interlobular septa but is much less pronounced in the interstitial, interalveolar septa. The histiocytes can be scarce within the fibrosis, which can make the diagnosis of Erdheim-Chester disease very difficult, especially if small biopsies are performed. Most of the lesional histiocytes show nuclear, as well as strong cytoplasmic expression for FXIIIa immunostain in ErdheimChester disease, whereas only nuclear expression is seen in intraalveolar macrophages (Figure 4d ). This finding is especially helpful in highlighting lesional histiocytes in Erdheim-Chester disease and differentiating Erdheim-Chester disease from the lesions of drug side effects and interstitial usual pneumonitis, which also harbor exuberant reactive histiocytic infiltrates and fibrosis. Of note, while pulmonary Langerhans cell histiocytosis is found almost exclusively in cigarette smokers, only one of the six patients with pulmonary Erdheim-Chester disease in the present study was a heavy smoker.
It merits particular emphasis that brain biopsy material from patients with Erdheim-Chester disease often fails to display the overtly xanthomatous histiocytic infiltration characteristic of this disorder in bony and other locations. Also, in contrast to meningeal and other tissue site involvement by Erdheim-Chester disease, fibroplasia typically does not occur within the brain parenchyma. Immunohistochemical assessment for expression of CD163 or other histiocytic 'markers' may be required to demonstrate both the presence and the enumeration of histiocytes, which may display ambiguous morphologic features leading to their misidentification as glial. The presence of perivascular lymphocytic cuffing may prompt misdiagnosis as a non-specific inflammatory process and florid astrogliosis with Rosenthal fiber formation may further obscure the picture. All relevant immunohistochemical methods must be employed to address a broad range of differential diagnostic considerations such as organizing infarct, demyelinating disease, Langerhans cell histiocytosis, and granular cell astrocytoma. The distinction of Erdheim-Chester disease from regressed primary central nervous system lymphoma is practically impossible in the absence of corroborating molecular diagnostic findings, radiologic and histologic confirmation of the expected skeletal involvement, or other patterns of extraneural disease that would support Erdheim-Chester disease. While Erdheim-Chester disease may involve the dura and cerebrum, a particularly high level of suspicion should be attached to histiocyte-rich lesions presenting in the pons and cerebellum.
Although Erdheim-Chester disease lesions generally lack a significant plasma cell infiltrate, some of the cases from retroperitoneal, orbital, and subcutaneous sites have abundant plasma cell infiltrate. This may be related to the special microenvironment of these sites. This finding often mimics IgG4-related disease, which also can frequently involve retroperitoneal and orbital tissues. The similarities between the Erdheim-Chester disease and IgG4-related disease include abundant fibrosis, the pseudonodular inflammatory infiltrate rich in lymphoplasmacytic cells, and the absence of cellular atypia. The presence of CD68(+)/CD1a( − ) foamy histiocytes and the absence IgG4 expressing plasma cells favor Erdheim-Chester disease. Fibrosis can be seen in both disorders but is often more prominent and dense in IgG4-related disease. Although none of our cases had an IgG4+ plasma cell rich infiltrate greater than the 40% cutoff value, some recent studies reported that IgG4+ plasma cells could exceed 40% in Erdheim-Chester disease lesions. 14 Therefore, it is important to take Erdheim-Chester disease into the differential for those lesions presenting in the retroperitoneum and orbit, even with large numbers of infiltrating IgG4+ plasma cells, with the suggestion for clinical and radiographical correlation.
In our cohort, there were only two testicular biopsies from known Erdheim-Chester disease patients, and both demonstrated Rosai-Dorfman disease-like morphology. There was no other biopsy sample from another site showing entirely RosaiDorfman disease-like morphological features in the remaining cases. In one of those cases (see Tables 1  and 2 , Patient 1) the same MAP2K1 mutation was detected in the testis (Rosai-Dorfman disease-like) and tongue (Erdheim-Chester disease-like) lesions of the patient. In the absence of a larger cohort of testicular biopsies, we can speculate whether this finding is truly an accompanying Rosai-Dorfman disease with a common progenitor sharing the same MAP2K1 mutation, as analogous to the Langerhans cell histiocytosis-Erdheim-Chester disease association with a common BRAF V600E mutation or a morphological manifestation of Erdheim-Chester disease in the testis microenvironment.
Immunophenotypic features of Erdheim-Chester disease are non-specific. Therefore immunohistochemical studies are supportive rather than diagnostic. Although S100 expression has been described in several Erdheim-Chester disease case reports, the exact frequency is not known, and it seems that nearly one third of Erdheim-Chester disease patients show some overexpression for this marker. Nevertheless, we did not note any Erdheim-Chester disease lesion with extensive expression of S100. Altogether our experience confirms the notion that S100 expression does not exclude Erdheim-Chester disease by any means, although robust expression was not found in any of our cases.
Immunohistochemistry using the VE1 antibody for detecting BRAF V600E mutant protein has been previously shown to be highly reliable in evaluation of melanoma, thyroid carcinoma, and hairy cell leukemia specimens. However, in BRAF V600E -mutated Erdheim-Chester disease, VE1-staining is generally very weak, scattered, and sometimes limited to only a few histiocytes. Furthermore, VE1 was negative in two of our biopsies harboring the BRAF V600E mutation by molecular analysis. Therefore, VE1-negative Erdheim-Chester disease cases have to be confirmed by BRAF V600E mutational analysis when adequate material is available.
Genetic data were available for 38 cases. Various molecular abnormalities were found, but strikingly, all of the mutations were within the MAPK pathway. Molecular studies are invaluable for supporting a diagnosis of Erdheim-Chester disease occurring in unusual sites or showing unusual morphological features, although we could not find any correlation between molecular findings, morphological or demographic features, or the sites of involvement.
Detection of somatic MAPK pathway mutations can also assist in the differential diagnosis of ErdheimChester disease and related histiocytic neoplasms. Both Erdheim-Chester disease and Langerhans cell histiocytosis share BRAF V600E mutation but unique patterns have emerged for other disorders. BRAF V600E mutations are not seen in juvenile xanthogranuloma and Rosai-Dorfman disease, whereas 18% of juvenile xanthogranuloma cases have been found to have an ARAF mutation 9 often co-occurring with activating NRAS mutations. Similarly, NRAS and KRAS mutations are present in 12.5 and 25% of Rosai-Dorfman disease patients; respectively. 9 Given these findings, the presence of a BRAF V600E mutation would support the diagnosis of Erdheim-Chester disease rather than juvenile xanthogranuloma, which are otherwise indistinguishable from each other by conventional histopathology.
A total of 42 cases have been included in our overview, and this is the largest number of Erdheim-Chester disease patients analyzed from a pathological perspective to date. The rarity of this disease and diversity of clinical and pathological features is a challenge for clinicians and pathologists alike. We hope that recognition of the broad spectrum of pathologic manifestations of ErdheimChester disease described in this study will help practicing clinicians and pathologists to diagnose Erdheim-Chester disease early in the disease course and manage these patients effectively.
